The ascendancy of Viagra and its effect on the medicinal landscape presents a complex question for shareholders. While the initial sales data were astounding, the exclusivity has lapsed, leading to a wave of copycat alternatives that are chipping away at earnings. Moreover, the market is facing issues related to population trends and shifting healt